SCHEMBL16220351

SCHEMBL16220351

CC(C)(C)OC(=O)N1CCC(c2cc(Nc3cc(C(F)(F)F)ccn3)nc(Cl)n2)CC1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.62
MAP3K12 Q12852 18/20 0.60
DLK1 P80370 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17507045 0.85 MAP3K12 (0.81) SYKMAP3K12
SCHEMBL17507044 0.85 MAP3K12 (0.81) SYKMAP3K12
SCHEMBL902839 0.79 SYK (0.60) SYKMAP3K12
SCHEMBL16220502 0.79 MAP3K12 (0.61) SYKMAP3K12DLK1
SCHEMBL17507061 0.79 MAP3K12 (0.59) SYKMAP3K12
SCHEMBL19826873 0.78 MAP3K12 (0.81) SYKMAP3K12DLK1
SCHEMBL19771678 0.77 MAP3K12 (0.73) SYKMAP3K12DLK1
SCHEMBL23579942 0.77 GPR119 (0.50)
SCHEMBL16220062 0.76 MAP3K12 (0.72) SYKMAP3K12DLK1
SCHEMBL16876405 0.76 SYK (0.73) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991977-B1 C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES HOFFMANN LA ROCHE (CH) 2020-07-22 EP disclosed
US-9868720-B2 C-linked heterocycloaklyl substituted pyrimidines and their uses GENENTECH, INC. (US) 2018-01-16 US disclosed
US-20160046608-A1 C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses GENENTECH, INC. (US) 2016-02-18 US disclosed
WO-2014177524-A1 C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046608-A1 C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses TYMS, DPYD, TYMP SYK 2556/4885MAP3K12 1825/4885DLK1 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.